Results 211 to 220 of about 110,851 (248)
Rare‐Variant Burden across Lysosomal Genes Implicates Sialylation and Ganglioside Metabolism in Parkinson's Disease
Movement Disorders, EarlyView.Abstract Background
Lysosomal dysfunction is central to Parkinson's disease (PD) pathogenesis, with GBA1 representing the strongest established genetic risk factor. Numerous other genes involved in lysosomal sphingolipid, glycosphingolipid, and ceramide metabolism have been proposed as contributors to PD, highlighting the need for genetic analyses ...Konstantin Senkevich, Sitki Cem Parlar, Cloe Chantereault, Lang Liu, Eric Yu, Uladzislau Rudakou, Jamil Ahmad, Jennifer A. Ruskey, Farnaz Asayesh, Dan Spiegelman, Cheryl Waters, Oury Monchi, Yves Dauvilliers, Nicolas Dupré, Lior Greenbaum, Sharon Hassin‐Baer, Irina Miliukhina, Alla Timofeeva, Anton Emelyanov, Sofya Pchelina, Roy N. Alcalay, Ziv Gan‐Or +21 morewiley +1 more sourcePlasmepsins as Antimalarial Drug Targets—Then, Now, and the Future
Medicinal Research Reviews, EarlyView.ABSTRACT
Malaria is a devastating disease caused by Plasmodium parasites. Plasmodium parasites express ten cathepsin D‐like aspartyl proteases, called plasmepsins (PMs). These PMs have diverse roles fulfill diverse functions throughout the parasite's lifecycle, though several exhibit functional redundancies. Among them, PMV, PMIV, and PMX are essential Brad E. Sleebswiley +1 more sourceSmall‐Molecule Kinase Inhibitors Modulating Circadian Rhythms
Medicinal Research Reviews, EarlyView.ABSTRACT
The circadian clock mechanism generates 24‐h rhythms crucial for regulating various physiological processes, and its dysregulation has been implicated in numerous diseases. In cells, the circadian clock operates through a transcriptional‐translational feedback loop, where phosphorylation plays a pivotal role in maintaining accurate circadian ...Irene Castellino, Manuela Bartolini, Rudolf Andrys, Kamil Musilek +3 morewiley +1 more sourceAt‐Home Versus in‐Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial
Muscle &Nerve, EarlyView.ABSTRACT Introduction/Aims
Respiratory weakness, typically monitored as vital capacity (VC), is a central feature of amyotrophic lateral sclerosis (ALS). VC is increasingly measured remotely in participants' homes, although in‐clinic assessment remains the standard.Eric A. Macklin, James D. Berry, Brittney A. Harkey, Lindsay Heyd, Marianne Chase, Hong Yu, Alexander V. Sherman, Derek Dagostino, Gale Kittle, Meghan Hall, Mariah R. Connolly, Kristin Drake, Elisa Giacomelli, Erica Scirocco, Saloni Sharma, Suma Babu, Michael Benatar, Zachary Simmons, Eufrosina Young, Merit E. Cudkowicz, Jeremy Shefner, Sabrina Paganoni, on behalf of the HEALEY ALS Platform Trial Study Group, Eric A. Macklin, Lori B. Chibnik, Douglas Hayden, Po‐Ying Lai, Rachel A. Donahue, Hao‐Wun Chen, Jianing Wang, Melanie Quintana, Benjamin R. Saville, Michelle A. Detry, Joe Marion, Matteo Vestrucci, Anna McGlothlin, Gustavo Alameda, Nithya Mathai, Eduardo Locatelli, Gabriela Lopes, Sabrina Paganoni, Merit Cudkowicz, Doreen Ho, Alexandra McCaffrey, James D. Berry, Suma Babu, Jennifer Scalia, Sarah Luppino, Clotilde Lagier‐Tourenne, Ghazaleh Sadri‐Vakili, Adam Quick, Stephen Kolb, Sarah Heintzman, Senda Ajroud‐Driss, Robert Sufit, April Szymanski, Jonathan Katz, Liberty Jenkins, Daragh Heitzman, Alan Martin, Stanley H. Appel, Simpson) Greene, Jason R. Thonhoff, Sheetal Shroff, Bing Liao, Kevin Felice, Charles Whitaker, Nicholas J. Maragakis, Lora L. Clawson, Alpa Uchil, Kristen M. Riley, JinAe Arneklev, Zachary Simmons, James Grogan, Xiaowei Su, Mansoureh Mamarabadi, Timothy M. Miller, Amber Malcolm, Nicholas Olney, Tracy Bazan, Michael D Weiss, Nassim Rad, Leo H. Wang, Stephen A. Goutman, Eva L. Feldman, Joseph Americo Fernandes, Ezequiel Piccione, Pariwat Thaisetthawatkul, Omar Jawdat, Constantine Farmakidis, Duaa Jabari, Jeffrey Statland, Mamatha Pasnoor, Mazen Dimachkie, Margaret Ayo Owegi, Robert H. Brown, Mehdi Ghasemi, Hajar Houmani, Catherine Douthwright, Kate Daniello, Laura A. Foster, Tuan Vu, Niraja Suresh, Jerrica Farias, I‐Hweii A. Chen, Hristelina Ilieva, Piera Pasinelli, Daniel S. Newman, Ximena Arcila‐Londono, Kara Steijlen, Carlayne E. Jackson, Ratna Bhavaraju‐Sanka, Shafeeq Ladha, Bill Jacobsen, Jourdan Milliard, Robert Bowser, Jeremy M. Shefner, Terry Heiman‐Patterson, Anahita Deboo, James B. Caress, Michael S. Cartwright, Andrea Swenson, Christopher Nance, Ludwig Gutmann, Jinsy Andrews, Julia Yasek, Matthew Harms, Amanda Peltier, Richard Lewis, Matthew Burford, Frank Diaz, Dominic Fee, David Shrilla, Matthew Elliott, Goran Rakocevic, Sarah Jones, Guillermo Solorzano, Richard Bedlack, Xiaoyan Li, Edward J. Kasarskis, Zabeen Mahuwala, Vishakhadatta (Vish) Mathur Kumaraswamy, Lauren Elman, Colin Quinn, Michael Baer, Jeffrey Rosenfeld, David Borg, Karthikeyan Bhuvaneswaran, Jasdeep Kaur, David Walk, Sam Maiser, Seward B. Rutkove, Courtney E. McIlduff, Paul Twydell, Andrew Mundwiler, Eufrosina Young, Jenny A. Meyer, Kristin Johnson, Pooja Rao, Kourosh Rezania, Betty Soliven, Raymond Roos, Namita A. Goyal, Ali A. Habib, Tahseen Mozaffar, Manisha Kak Korb, Jeffrey Mullen, Jeffrey A. Cohen, Elijah Stommel, Nathaniel M Robbins, Michael Benatar, Nathan Carberry, Volkan Granit, Raghav Govindarajan, Vovanti Jones, Jonathan Glass, Christina N. Fournier, Jaimin S. Shah, Bjorn Oskarsson, Said R. Beydoun, Leila Darki, Rodrigo Rodriguez, James P. Wymer, Miguel Chuquilin, Whitney McNeely, Lindsay Zilliox, Montserrat Diaz‐Abad, Peter H. Jin, Chandana Chauhan, Shakti Nayar, Gary L. Pattee, James Bobenhouse, Jennifer Martinez‐Thompson, Nathan P. Staff, Ghazala Hayat, Luisa Arroyave, Abbey Bailey, Jesse Bailey, Victoria Barlow, Allison Bulat, Genevive Changkuon, Marianne Chase, Melissa Cirino, Derek Dagostino, Cristina Deignan, Emma Deirmendjian, Annette De Mattos, Sofia DiStefano, Kristin Drake, Michaela Estes, Kenneth Faulconer, Precious Figueroa‐Szostek, Tessa Garozzo, Brittney A. Harkey, Meredith Gibbons Hasenoehrl, Jennifer Henrique, Natalie Henrique, Samuel Hurwitz, Courtney Igne, Liam Irwin, Katie Jentoft, Boglarka Jordan, Igor Katsovskiy, Olga Kharakozova, Taylor Kolvek, Alexander Korin, Thuong La, Haining Li, Joey Nguyen, Ilya Novak, Ricardo Ortiz, Joe Ostrow, Jaclyn Pagliaro, Jack Palillo, Payal Patel, Janae Patterson, Minh Phan, Najla Popel, Lindsay Pothier, Serena Proueng, Jesse Rosenthal, Alexander V. Sherman, Catherine Small, Natalia Tarasenko, Mirna Thomas, Eric Tustison, Prasha Vigneswaran, Yusra Wahab, Isaac Whitworth, Spencer Wright, Hong Yu, Mariah Connolly, Diana De Santiago, Adrian Felix, Karly Garrett, Meghan Hall, Jenny Hamilton, Kamran Khan, Gale Kittle, Marlee Lovett, Linda Nelson, Marissa Pabon, Diana Rede, Patrick Bolger, Ahmed Fetouh, Joan Woodcook, Cornelia Kamp, Julie Kennedy, Andrew McGarry, Margherita Torti +269 morewiley +1 more sourceSome of the next articles are maybe not open access.Related searches:
Schizophrenia as a GSK-3 dysregulation disorder
Trends in Neurosciences, 2007 Converging evidence suggests that the regulation of glycogen synthase kinase 3 (GSK-3) might be important in schizophrenia. Atypical and typical antipsychotic drugs alter GSK-3 activity, as do drugs that induce psychosis. GSK-3 regulatory pathways are altered in schizophrenia, and many of the genes associated with schizophrenia directly or indirectly ...Lovestone, S, Killick, R, Di Forti, M, Murray, R +3 moreopenaire +3 more sourcesGSK-3 and the neurodevelopmental hypothesis of schizophrenia
European Neuropsychopharmacology, 2002 The Neurodevelopmental Hypothesis of schizophrenia suggests that interaction between genetic and environmental events occurring during critical early periods in neuronal growth may negatively influence the way by which nerve cells are laid down, differentiated and selectively culled by apoptosis.Nitsan, Kozlovsky, R H, Belmaker, Galila, Agam +2 moreopenaire +2 more sourcesAnti-inflammatory Potential of GSK-3 Inhibitors
Current Drug Targets, 2021 Glycogen synthase kinase-3 (GSK-3) is a protein kinase containing threonine or serine amino acid residues. GSK-3 was first discovered in 1980 as a regulatory protein kinase, Glycogen synthase (GS) enzyme, which is responsible for the conversion of glycogen from glucose with the help of uridine diphosphate glucose (UDP-Glu) residue.Chandi C. Kandar, Debanjan Sen, Arindam Maity +2 moreopenaire +2 more sourcesCdc42 & GSK-3: signals at the crossroads
Nature Cell Biology, 2003 Cell polarity is regulated by independent pathways that are controlled by Wnt- or Cdc42-mediated signalling. Now, glycogen synthase kinase 3 (GSK-3), an established component of the Wnt pathway, is shown to interact with Par6–protein kinase C ζ (PKCζ), a complex that transduces Cdc42 signals.Adrian, Harwood, Vania M M, Bragaopenaire +2 more sourcesNovel pyrazolopyrimidine derivatives as GSK-3 inhibitors
Bioorganic & Medicinal Chemistry Letters, 2004 A series of [1-aryl-1H-pyrazolo[3,4-d]pyrimidin-4-yl]arylhydrazones were discovered as novel inhibitors glycogen synthase kinase-3 (GSK-3). Based on initial modeling a detailed SAR was constructed. Modification of the interior binding aryl ring (Ar(1)) determined this to be a tight binding region with little room for modification. As predicted from the Andrew J, Peat, Joyce A, Boucheron, Scott H, Dickerson, Dulce, Garrido, Wendy, Mills, Jennifer, Peckham, Frank, Preugschat, Terrence, Smalley, Stephanie L, Schweiker, Jayme R, Wilson, Tony Y, Wang, Huiqiang Q, Zhou, Stephen A, Thomson +12 moreopenaire +2 more sourcesEffect of GSK-3 overactivation on neurofilament phosphorylation
Journal of Huazhong University of Science and Technology [Medical Sciences], 2005 In this study, we studied the effect of glycogen synthase kinase-3 (GSK-3) overactivation on neurofilament phosphorylation in cultured cells. After N2a cells were treated with the specific inhibitor (wortmannin) of phosphoinositol-3 kinase (PI-3K) or treated with wortmannin and the specific inhibitor (LiCl) of glycogen synthase kinase-3 (GSK-3), GSK-3 ...Juan, Chen, Jie, Zhou, Youmei, Feng, Jianzhi, Wang +3 moreopenaire +2 more sources
